PXT3003
( DrugBank: - / KEGG DRUG: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 10 | Charcot-Marie-Tooth disease | 24 |
10. Charcot-Marie-Tooth disease
Clinical trials : 41 / Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15
Showing 1 to 10 of 24 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004805-30-DK (EUCTR) | 31/01/202220220131 | 08/06/202120210608 | Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ... | Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ... | Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclofen INN or Proposed INN: NALTREXONE Other descriptive name: naltrexone hydrochloride INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ... | Pharnext SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Phase 3 | France;United States;Canada;Spain;Belgium;Denmark;Israel;Netherlands;Germany;Italy | ||
| 2 | EUCTR2020-004805-30-NL (EUCTR) | 23/09/202120210923 | 27/05/202120210527 | Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ... | Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ... | Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclofen INN or Proposed INN: NALTREXONE Other descriptive name: naltrexone hydrochloride INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ... | Pharnext SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Phase 3 | France;United States;Canada;Spain;Belgium;Denmark;Israel;Germany;Netherlands;Italy | ||
| 3 | EUCTR2020-004805-30-IT (EUCTR) | 19/05/202120210519 | 02/08/202120210802 | Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) - na A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ... | Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ... | Product Name: PXT3003 Product Code: [PXT3003] INN or Proposed INN: BACLOFENE INN or Proposed INN: NALTREXONE CLORIDRATO Other descriptive name: naltrexone hydrochloride INN or Proposed INN: SORBITOLO Other descriptive name: D-SORBITOL Product Name: PXT3003 Product Code: [PXT3003] INN or Proposed INN: BACLOFENE INN or Proposed INN: NALTR ... | Pharnext SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Phase 3 | France;United States;Canada;Spain;Belgium;Denmark;Israel;Netherlands;Germany;Italy | ||
| 4 | EUCTR2020-004805-30-ES (EUCTR) | 04/05/202120210504 | 30/07/202120210730 | Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ... | Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ... | Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclofen INN or Proposed INN: NALTREXONE Other descriptive name: naltrexone hydrochloride INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ... | Pharnext SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Phase 3 | France;United States;Canada;Belgium;Spain;Denmark;Israel;Netherlands;Germany;Italy | ||
| 5 | EUCTR2020-004805-30-FR (EUCTR) | 04/05/202120210504 | 19/01/202220220119 | Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ... | Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ... | Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclofen INN or Proposed INN: NALTREXONE Other descriptive name: naltrexone hydrochloride INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ... | Pharnext SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 350 | Phase 3 | United States;France;Canada;Spain;Belgium;Denmark;Israel;Netherlands;Germany;Italy | ||
| 6 | NCT04762758 (ClinicalTrials.gov) | March 30, 202120210330 | 17/2/202120210217 | Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients | A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A) A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, ... | Charcot-Marie-Tooth Disease | Drug: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol;Drug: Placebo | Pharnext SA | Worldwide Clinical Trials | Active, not recruiting | 16 Years | 65 Years | All | 350 | Phase 3 | United States;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Spain;Netherlands |
| 7 | EUCTR2015-002379-81-NL (EUCTR) | 08/01/201820180108 | 28/03/201720170328 | An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003in ... | International, multi-center, open-label FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. International, multi-center, open-label FOLLOW-UP extension study assessing the long term safety and ... | Charcot-Marie-Tooth Disease type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot-Marie-Tooth Disease type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Ter ... | Product Code: PXT3003 Dose 1 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003 Dose 2 (equivalent to twice Dose 1) INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003Dose 1 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed IN ... | Pharnext SA | NULL | Not Recruiting | Female: yes Male: yes | 186 | Phase 3 | France;United States;Canada;Spain;Belgium;Germany;Netherlands;United Kingdom | ||
| 8 | EUCTR2015-002379-81-DE (EUCTR) | 15/08/201720170815 | 19/01/201720170119 | An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of P ... | International, multi-center, open-label 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. International, multi-center, open-label 9-month FOLLOW-UP extension study assessing the long term sa ... | Charcot-Marie-Tooth Disease type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot-Marie-Tooth Disease type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Ter ... | Product Code: PXT3003 Dose 2 (equivalent to twice Dose 1) INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003 Dose 2 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003Dose 2 (equivalent to twice Dose 1) INN or Proposed INN: BACLOFEN Other descripti ... | Pharnext | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 3 | France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom | ||
| 9 | EUCTR2015-002379-81-GB (EUCTR) | 28/07/201720170728 | 12/06/201720170612 | An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. An International, multi-center, FOLLOW-UP extension study to study the long term safety of PXT3003in ... | International, multi-center, open-label FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. International, multi-center, open-label FOLLOW-UP extension study assessing the long term safety and ... | Charcot-Marie-Tooth Disease type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot-Marie-Tooth Disease type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Ter ... | Product Code: PXT3003 Dose 1 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003 Dose 2 (equivalent to twice Dose 1) INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003Dose 1 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed IN ... | Pharnext SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 187 | Phase 3 | United States;France;Canada;Spain;Belgium;Germany;Netherlands;United Kingdom | ||
| 10 | EUCTR2015-002379-81-ES (EUCTR) | 25/05/201720170525 | 07/04/201720170407 | An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of P ... | International, multi-center, double blind 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A. International, multi-center, double blind 9-month FOLLOW-UP extension study assessing the long term ... | Charcot-Marie-Tooth Disease type 1A MedDRA version: 19.1;Level: LLT;Classification code 10008414;Term: Charcot-Marie-Tooth disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Charcot-Marie-Tooth Disease type 1A MedDRA version: 19.1;Level: LLT;Classification code 10008414;Ter ... | Product Code: PXT3003 Dose 1 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003 Dose 2 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed INN: NALTREXONE Other descriptive name: NALTREXONE HYDROCHLORIDE INN or Proposed INN: Sorbitol Other descriptive name: D-SORBITOL Product Code: PXT3003Dose 1 INN or Proposed INN: BACLOFEN Other descriptive name: NA INN or Proposed IN ... | Pharnext | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 3 | France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom |